Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies

Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies

Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synerg...

Full description

Bibliographic Details
Main Authors: Ayuda-Durán, P. (Author), Brown, J.R (Author), Enserink, J. (Author), Giliberto, M. (Author), Hanes, R. (Author), Holien, T. (Author), Karlsen, L. (Author), Melvold, K. (Author), Skånland, S.S (Author), Taskén, K. (Author), Tjønnfjord, G.E (Author)
Format: Article
Language:English
Published: John Wiley and Sons Ltd 2022
Subjects:
cell signaling
chronic lymphocytic leukemia
drug sensitivity
mantle cell lymphoma
MEK inhibitors
multiple myeloma
phospho flow
synergy
venetoclax
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items